Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 7 days
Any time
Past hour
Past 24 hours
Past 30 days
Most recent
Best match
Seeking Alpha
17h
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
I will also explain why I upgraded OGN stock to buy from hold, despite the additional uncertainty stemming from the Dermavant ...
The Motley Fool
1d
Roivant Sciences Posts Mixed Q2
One critical focus for Roivant Sciences is its pipeline. Its success is heavily reliant on products like VTAMA, currently ...
dermatologyadvisor
2d
FDA Extends Review of Tapinarof Cream for Atopic Dermatitis
The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Republicans win the House
Picked as secretary of state
Next Senate majority leader
Declines WH invitation
Reveals cancer diagnosis
Died of septic shock
‘I was not paid a dime’
Freevee to shut down
US streamer indicted in SK
Recuses self from AZ case
Pulled from lunch program
Bid to delay trial rejected
How to watch fight?
US missile base in Poland
Recalling pickups, SUVs
2,400+ Cybertrucks recalled
Russia attacks Kyiv
Repairs to cost nearly $56M
Amtrak service disrupted
US strikes Iran-linked group
Tests negative for rabies
Trump, Biden meet at WH
Consumer inflation picks up
Jazz musician dies at 99
Former solicitor general dies
US govt. worker charged
To face US antitrust trial
Jack Smith to resign?
Bitcoin rises above $90K
Feedback